

## Oregon Drug Use Review Board

Office of Medical Assistance Programs  
State of Oregon  
May 7, 2002  
Meeting Minutes

The meeting was held at the Department of Human Services Building, 500 Summer Street NE, Salem, Room 137ab.

### I. CALL TO ORDER

- a. Roll call was taken. Guests were introduced. The meeting was called to order by Ch. Asai at 1:37. A quorum was present.
- b. The minutes were approved with no corrections.
- c. Conflict of Interest statements were reviewed. One question was raised regarding the importance of disclosing spouse's COI.
- d. There was no public comment.

### II. OLD BUSINESS

#### a. Anticonvulsant Use Review

In light of the current politics involved with the HRC subcommittee and based on feedback from clinical experts, the College of Pharmacy withdrew their recommendations to create prior authorization criteria for the newer anticonvulsants (gabapentin, topiramate and lamictal) at this time.

#### b. Sedative Hypnotic Quantity Limits

Mr. Drawbaugh reported that there was support for this approach to limiting inappropriate chronic sedative therapy and that a careful, delivered approach would be best. Currently there is no timetable.

#### c. Bronchodialator Utilization Review

Tabled

#### d. Child Vaccination DUE

Tabled

### III. REPORTS

#### a. Drug Utilization PMPM Report

The Board reviewed the report.

**Action: The Board recommended that the bronchodilator DUR would be helpful in determining the elevated cost in this drug class. The Board would like to see this addressed at the next meeting.**

**b. ProDUR Alert by Class**

The Board reviewed the report.

**c. Antihistamine Literature Review**

The Board reviewed and appreciated this comprehensive review.

**d. Antihistamine Utilization Review**

The Board reviewed this report.

**Action: The Board is interested in knowing the number of allergists that prescribe non-sedating antihistamines as this group of specialists bypass the edit.**

**e. ProDUR Report**

The Board reviewed ProDUR criteria for antihistamine drugs. There were no objections to any of the mentioned changes.

**f. RetroDUR Report**

The Board reviewed the report. Ms. Hope reported that the Council filled the pharmacist vacancy (Eric Rimkus of Walgreen's) and is currently recruiting for a physician to replace Cynthia Younger.

The Board discussed the need to improve compliance with reporting provider IDs. Pharmacists are hoping for a time-saving process to make this easier.

**g. Education Report**

Dr. Haxby reported that recent topics of the monthly DUR Board Newsletter have included Lipid Therapy and ADHD. Upcoming topics will include chronic pain and urinary incontinence.

**Action: The Board would like to see a small article written on the difference between Depakote DR and ER. The two formulations are often used interchangeably and this is inappropriate.**

**h. Health Resources Commission Report & Pharmacy Program Update**

Mr. Drawbaugh reported that the Committee is close to completing the review of the first groups of the drugs (LA opiates, PPIs, NSAIDs, Statins). Reviews are available on the OHPR website at [www.ohppr.state.or.us](http://www.ohppr.state.or.us). The second groups of drugs (ACEIs & ARBs, CCBs, triptans and estrogens) are open to comment through the end of May.

Mr. Drawbaugh reported that the submitted rule changes for PPIs were withdrawn due to the PMPDP.

Mr. Drawbaugh reported that the proposed change in drug reimbursement to AWP-14% is planned for July 1, 2002. In addition, the optional copay, pharmacy lock-in, and inclusion of diagnosis on prescriptions are also estimated to start July

1, 2002.

#### **IV. NEW BUSINESS**

##### **a. Annual Report**

Ms. Rich reported that the annual report will be sent to CMS with the Board's approval. Board was appreciative of the work done compiling and preparing the report.

Next meeting is scheduled for September 10, 2002, in DHS 137CD at 1:30-4:30 PM.

The meeting adjourned at approximately 3:05 PM by Ch. Asai.

Minutes respectfully submitted by Ann Hamer.